BidaskClub downgraded shares of Sangamo Therapeutics (NASDAQ:SGMO) from a strong-buy rating to a buy rating in a report published on Saturday.
A number of other analysts have also commented on the company. Barclays initiated coverage on Sangamo Therapeutics in a research note on Wednesday, November 22nd. They issued an overweight rating and a $20.00 price target for the company. Piper Jaffray Companies set a $25.00 price target on Sangamo Therapeutics and gave the stock a buy rating in a research note on Wednesday, January 3rd. Jefferies Group reaffirmed a buy rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Zacks Investment Research lowered Sangamo Therapeutics from a buy rating to a hold rating in a research note on Friday, January 5th. Finally, Wedbush reaffirmed a neutral rating and issued a $6.00 price target on shares of Sangamo Therapeutics in a research note on Monday, February 12th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $20.83.
Shares of Sangamo Therapeutics (NASDAQ:SGMO) opened at $23.10 on Friday. Sangamo Therapeutics has a 52 week low of $3.85 and a 52 week high of $27.50. The company has a market capitalization of $2,028.97, a price-to-earnings ratio of -33.00 and a beta of 2.60. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 0.13.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. Sangamo Therapeutics had a negative return on equity of 31.44% and a negative net margin of 149.23%. The company had revenue of $13.08 million during the quarter, compared to analyst estimates of $11.10 million. During the same quarter last year, the firm posted ($0.14) earnings per share. The firm’s revenue was up 46.6% on a year-over-year basis. analysts expect that Sangamo Therapeutics will post -0.15 EPS for the current fiscal year.
In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $25.56, for a total transaction of $127,800.00. Following the completion of the transaction, the chief financial officer now owns 12,250 shares of the company’s stock, valued at $313,110. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Curt A. Herberts III sold 15,000 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $17.26, for a total value of $258,900.00. Following the transaction, the vice president now directly owns 13,015 shares of the company’s stock, valued at approximately $224,638.90. The disclosure for this sale can be found here. Insiders have sold 95,403 shares of company stock valued at $2,035,169 in the last three months. Insiders own 5.50% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its position in Sangamo Therapeutics by 2.1% during the fourth quarter. BlackRock Inc. now owns 6,871,509 shares of the biopharmaceutical company’s stock valued at $112,691,000 after buying an additional 138,348 shares during the period. State Street Corp increased its holdings in shares of Sangamo Therapeutics by 51.6% during the second quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock valued at $16,441,000 after acquiring an additional 636,296 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Sangamo Therapeutics by 15.8% during the fourth quarter. Teachers Advisors LLC now owns 946,128 shares of the biopharmaceutical company’s stock valued at $15,516,000 after acquiring an additional 128,743 shares in the last quarter. Alexandria Capital LLC bought a new position in shares of Sangamo Therapeutics during the fourth quarter valued at $15,179,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Sangamo Therapeutics by 58.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 911,512 shares of the biopharmaceutical company’s stock valued at $14,948,000 after acquiring an additional 336,107 shares in the last quarter. 64.68% of the stock is owned by institutional investors and hedge funds.
WARNING: “Sangamo Therapeutics (SGMO) Cut to “Buy” at BidaskClub” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://ledgergazette.com/2018/03/20/sangamo-therapeutics-sgmo-cut-to-buy-at-bidaskclub.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.